Phathom Pharmaceuticals, Inc. (PHAT) income statement
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30
$5.30−0.20 (-3.64%)
Close on Nov 18, 2026Market cap $430.85MP/E –Yield –
Phathom Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 80.7%
- Operating margin
- -9.3%
- Net margin
- -30.2%
- Return on equity, FY2025
- 64.0%
Financial strength
- Current ratio
- 1.76
- Debt to equity
- -0.48
- Debt to assets
- 48.0%
- Cash to current liabilities
- 105.5%
Valuation
- P/E ratio
- –
- Price to sales
- 1.57
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?